IMMUNOHEMATOLOGY - RH-HR, KELL, KIDD, DUFFY - MONOCLONAL ORIGIN - ANVISA Registration 80115310119
Access comprehensive regulatory information for IMMUNOHEMATOLOGY - RH-HR, KELL, KIDD, DUFFY - MONOCLONAL ORIGIN in Brazil's medical device market through Pure Global AI's free database. This Risk Class IV medical device is registered under ANVISA number 80115310119 and manufactured by manufacturer not specified. The registration is held by KOVALENT DO BRASIL LTDA with validity until Aug 11, 2033.
This page provides complete technical specifications for 2 related devices, regulatory compliance details, 5 companies making the same product including IMMUCOR MEDIZINISCHE DIAGNOSTIK GMBH, MEDION GRIFOLS DIAGNOSTICS AG, and 5 recent registrations in the same technical category. Pure Global AI offers free access to over 100,000+ Brazilian medical device registrations, helping global MedTech companies navigate ANVISA regulations, identify competitors, and discover partnership opportunities efficiently.
Related Devices (2)
Registration Details
80115310119
25351297162200786
04842199000156
Company Information
Dates and Status
Aug 11, 2008
11/08/2033
09/18/2025 19:00:01
IMUNOHEMATOLOGIA - RH-HR, KELL, KIDD, DUFFY - ORIGEM MONOCLONAL
FAMรLIA: REAGENTES PARA IMUNOHEMATOLOGIA - Rh-Hr - KELL, KIDD, DUFFY- NACIONAL
BIO-RAD LABORATORIOS BRASIL LTDA.
80020690465
Jul 14, 2025
IMUNOHEMATOLOGIA - RH-HR, KELL, KIDD, DUFFY - ORIGEM MONOCLONAL
Famรญlia RH-HR, KELL, KIDD, DUFFY Monoclonal Importado โ Gel Teste
Not specified
80020690472
Jul 14, 2025
IMUNOHEMATOLOGIA - RH-HR, KELL, KIDD, DUFFY - ORIGEM MONOCLONAL
Famรญlia RH-HR, KELL, KIDD, DUFFY Monoclonal Importado โ Gel Teste
DIAMED GMBH
80020690472
Jul 14, 2025
IMUNOHEMATOLOGIA - RH-HR, KELL, KIDD, DUFFY - ORIGEM MONOCLONAL
FAMรLIA RH-HR, KELL, KIDD, DUFFY MONOCLONAL IMPORTADO- CONVENCIONAL
DIAMED GMBH
80020690474
Jul 14, 2025
IMUNOHEMATOLOGIA - RH-HR, KELL, KIDD, DUFFY - ORIGEM MONOCLONAL
FAMรLIA RH-HR, KELL, KIDD, DUFFY MONOCLONAL IMPORTADO- CONVENCIONAL
Not specified
80020690474
Jul 14, 2025

